Sun Pharma Advanced Research Company Limited (SPARC) has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company’s Board of Directors approved the financial statements, which include details on revenue from operations, total income, expenses, and profit/loss for the periods. Key figures for the quarter show a total revenue of ₹3,003 Lakhs and a profit after tax of ₹(2,458) Lakhs on a standalone basis.
SPARC Announces Quarterly and Half-Yearly Financial Results
Sun Pharma Advanced Research Company Limited (SPARC) has officially released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The outcomes of the Board of Directors’ meeting held on November 2, 2026, confirm the approval and consideration of these financial statements.
Standalone Financial Highlights
For the quarter ended September 30, 2026, SPARC reported total revenue from operations of ₹3,003 Lakhs. The total income for the same period stood at ₹5,365 Lakhs, while total expenses amounted to ₹7,823 Lakhs. Consequently, the company posted a profit/(loss) before tax of ₹(2,458) Lakhs and a profit/(loss) for the period after tax of ₹(2,458) Lakhs. The total comprehensive profit/(loss) for the period was ₹(2,622) Lakhs.
On a half-year basis, from April 01, 2026, to September 30, 2026, the total revenue from operations was ₹6,995 Lakhs. The profit/(loss) before tax was ₹(4,556) Lakhs, and the profit/(loss) for the period after tax was also ₹(4,556) Lakhs. The total comprehensive profit/(loss) for the half year stood at ₹(4,720) Lakhs.
Consolidated Financial Overview
The consolidated financial results present a similar trend. For the quarter ended September 30, 2026, consolidated total revenue from operations was ₹3,003 Lakhs, with a consolidated profit/(loss) for the period of ₹(2,439) Lakhs. The consolidated total comprehensive profit/(loss) for the quarter was ₹(2,596) Lakhs.
For the half year ended September 30, 2026, the consolidated total revenue from operations was ₹6,995 Lakhs. The consolidated profit/(loss) before tax was ₹(4,498) Lakhs, and the consolidated profit/(loss) for the period was ₹(4,517) Lakhs. The consolidated total comprehensive profit/(loss) for the half year amounted to ₹(4,672) Lakhs.
Key Notes and Disclosures
The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS). Notable disclosures include an exceptional item recognized in the previous year related to the ‘New Labour Codes’ amounting to ₹1,236 Lakhs. Additionally, the company provided details on the termination of a licensing agreement, a refund, and income recognized from a Priority Review Voucher (PRV).
The company also detailed a preferential allotment of warrants on May 19, 2026, involving 3,85,10,000 warrants. SPARC operates in a single reportable business segment: ‘Pharmaceutical Research and Development’.
Source: BSE
